Mid-cap Health Care company Exelixis has moved -0.6% so far today on a volume of 545,477, compared to its average of 2,298,606. In contrast, the S&P 500 index moved 0.0%.
Exelixis trades -15.84% away from its average analyst target price of $25.82 per share. The 17 analysts following the stock have set target prices ranging from $18.0 to $32.0, and on average have given Exelixis a rating of buy.
If you are considering an investment in EXEL, you'll want to know the following:
-
Exelixis has moved 33.0% over the last year, and the S&P 500 logged a change of 17.0%
-
Based on its trailing earnings per share of 0.29, Exelixis has a trailing 12 month Price to Earnings (P/E) ratio of 74.9 while the S&P 500 average is None
-
EXEL has a forward P/E ratio of 24.1 based on its forward 12 month price to earnings (EPS) of $0.9 per share
-
The company has a price to earnings growth (PEG) ratio of 1.89 — a number near or below 1 signifying that Exelixis is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 2.88 compared to its sector average of None
-
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
-
Based in Alameda, the company has 1,223 full time employees and a market cap of $6.76 Billion.